Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Technology

Technology Overview

Optimize Patient Outcomes

Meet your heart failure (HF) patients' changing needs with our latest generation of CRT technology:

SyncAV™ Plus CRT technology offers dynamic AV timing to ensure electrical resynchronization.


22% fewer HF hospitalizations
for patients with SyncAV™ CRT technology enabled vs. patients with the technology disabled1


100% of patients
had a narrower QRS2

MultiPoint™ pacing delivers multiple LV pacing pulses per cardiac cycle in both LV-only and biventricular pacing modes.


87% response rate
shown in the IDE study subgroup with anatomically programmed separation3


In a separate study, MultiPoint pacing led to significantly more responders and fewer non-responders vs. biventricular pacing (p <0.05)4

Faster, More Intuitive Programming

Gallant HF CRT-D solutions offer simple setup and customizable programming:

  • 2X faster vector testing
  • 13 vectors and 4 pacing electrodes provide more options and greater control

  • Gallant HF CRT-D Programming Guide

    Gallant HF CRT-D Programming Guide

    Download

This device is commercially available for use in select international markets.

References

  1. Varma, N., Gain in CRT Efficacy with Dynamic Electrical Optimization: Real World Effect of SyncAV™ CRT on Heart Failure Hospitalizations. Poster presented at EHRA. May 2020. https://www.escardio.org/Sub-specialty-communities/European-Heart-Rhythm-Association-%28EHRA%29/Researchand-Publications/EHRA-Essentials-4-You#lbt. Accessed May 15, 2020.
  2. Varma N, O’Donnell D, Bassiouny M, et al. Programming cardiac resynchronization therapy for electrical synchrony: reaching beyond left bundle branch block and left ventricular activation delay. J Am Heart Assoc. 2018;7:e007489. https://www.ahajournals.org/doi/10.1161/JAHA.117.007489. Accessed January 14, 2020.
  3. Niazi, et al. Safety and efficacy of multipoint pacing in cardiac resynchronization therapy—the multipoint pacing trial. JACC: Clinical Electrophysiology. Volume 3, Issue 13, 26 December 2017, Pages 1519-1522. https://doi.org/10.1016/j.jacep.2017.06.022. Accessed January 14, 2020.
  4. Musaad AMA, Bokhari F, Sweidan R, et al. Long term effect of MultiPoint Pacing in Heart Failure patients on end systolic volume: preliminary results from a randomized and multicenter study in the Middle East. APHRS presentation, 2019.

MAT-2008665 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo